Does the media refer more to ENGN or AQST?

In the previous week, enGene had 4 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 5 mentions for enGene and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat enGene's score of 0.08 indicating that Aquestive Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aquestive Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ENGN or NVCT?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is ENGN or NVCT more profitable?

enGene's return on equity of -56.06% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Nuvectis Pharma N/A -161.00% -98.88%

Which has better valuation & earnings, ENGN or VALN?

enGene has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Valneva $197.56M 2.32 -$130.33M -$1.87 N/A

Is ENGN or VALN more profitable?

enGene has a net margin of 0.00% compared to Valneva's net margin of -88.87%. enGene's return on equity of -56.06% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Valneva -88.87% -107.63% -33.02%

Does the media prefer ENGN or VALN?

In the previous week, enGene had 4 more articles in the media than Valneva. MarketBeat recorded 5 mentions for enGene and 1 mentions for Valneva. Valneva's average media sentiment score of 0.22 beat enGene's score of 0.08 indicating that Valneva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valneva 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, ENGN or OCGN?

Ocugen has higher revenue and earnings than enGene. Ocugen is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Ocugen $4.41M 102.09 -$67.85M -$0.24 N/A

Is ENGN or OCGN more profitable?

enGene's return on equity of -56.06% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Ocugen N/A -127,987.80% -135.48%

Does the media refer more to ENGN or OCGN?

In the previous week, enGene had 4 more articles in the media than Ocugen. MarketBeat recorded 5 mentions for enGene and 1 mentions for Ocugen. Ocugen's average media sentiment score of 0.34 beat enGene's score of 0.08 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ENGN or KYTX?

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio enGene N/A N/A -$117.30M -$2.17 N/A Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A

Is ENGN or KYTX more profitable?

enGene's return on equity of -56.06% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -56.06% -45.64% Kyverna Therapeutics N/A -81.88% -64.87%

Does the media prefer ENGN or KYTX?

In the previous week, enGene had 4 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for enGene and 1 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.34 beat enGene's score of 0.08 indicating that Kyverna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment enGene 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyverna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

enGene (ENGN) Competitors

$1.87 +0.05 (+2.75%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$1.88 +0.01 (+0.53%)

As of 07:32 AM Eastern

Compare

ENGN vs. AQST, NVCT, VALN, OCGN, and KYTX

Should you buy enGene stock or one of its competitors? MarketBeat compares enGene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with enGene include Aquestive Therapeutics (AQST), Nuvectis Pharma (NVCT), Valneva (VALN), Ocugen (OCGN), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry.

How does enGene compare to Aquestive Therapeutics?

enGene (NASDAQ:ENGN) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

enGene has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

In the previous week, enGene had 4 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 5 mentions for enGene and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.34 beat enGene's score of 0.08 indicating that Aquestive Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aquestive Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aquestive Therapeutics has higher revenue and earnings than enGene. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Aquestive Therapeutics	$44.54M	11.10	-$83.78M	-$0.61	N/A

enGene currently has a consensus target price of $11.05, indicating a potential upside of 490.67%. Aquestive Therapeutics has a consensus target price of $8.50, indicating a potential upside of 115.74%. Given enGene's higher possible upside, research analysts plainly believe enGene is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

64.2% of enGene shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 10.5% of enGene shares are owned by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

enGene has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Summary

Aquestive Therapeutics beats enGene on 8 of the 15 factors compared between the two stocks.

How does enGene compare to Nuvectis Pharma?

enGene (NASDAQ:ENGN) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market.

Nuvectis Pharma is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

enGene's return on equity of -56.06% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Nuvectis Pharma	N/A	-161.00%	-98.88%

64.2% of enGene shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, enGene had 5 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for enGene and 0 mentions for Nuvectis Pharma. enGene's average media sentiment score of 0.08 beat Nuvectis Pharma's score of 0.00 indicating that enGene is being referred to more favorably in the media.

Company	Overall Sentiment
enGene	Neutral
Nuvectis Pharma	Neutral

enGene presently has a consensus price target of $11.05, suggesting a potential upside of 490.67%. Nuvectis Pharma has a consensus price target of $35.00, suggesting a potential upside of 94.12%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

enGene beats Nuvectis Pharma on 7 of the 13 factors compared between the two stocks.

How does enGene compare to Valneva?

enGene (NASDAQ:ENGN) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

enGene presently has a consensus price target of $11.05, indicating a potential upside of 490.67%. Valneva has a consensus price target of $11.98, indicating a potential upside of 147.42%. Given enGene's higher possible upside, equities analysts clearly believe enGene is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

enGene has higher earnings, but lower revenue than Valneva. Valneva is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Valneva	$197.56M	2.32	-$130.33M	-$1.87	N/A

In the previous week, enGene had 4 more articles in the media than Valneva. MarketBeat recorded 5 mentions for enGene and 1 mentions for Valneva. Valneva's average media sentiment score of 0.22 beat enGene's score of 0.08 indicating that Valneva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

64.2% of enGene shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Valneva has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

enGene has a net margin of 0.00% compared to Valneva's net margin of -88.87%. enGene's return on equity of -56.06% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Valneva	-88.87%	-107.63%	-33.02%

Summary

enGene beats Valneva on 8 of the 15 factors compared between the two stocks.

How does enGene compare to Ocugen?

enGene (NASDAQ:ENGN) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

enGene has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market.

In the previous week, enGene had 4 more articles in the media than Ocugen. MarketBeat recorded 5 mentions for enGene and 1 mentions for Ocugen. Ocugen's average media sentiment score of 0.34 beat enGene's score of 0.08 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

enGene's return on equity of -56.06% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Ocugen	N/A	-127,987.80%	-135.48%

64.2% of enGene shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 4.0% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

enGene presently has a consensus target price of $11.05, suggesting a potential upside of 490.67%. Ocugen has a consensus target price of $9.50, suggesting a potential upside of 614.29%. Given Ocugen's stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Ocugen has higher revenue and earnings than enGene. Ocugen is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Ocugen	$4.41M	102.09	-$67.85M	-$0.24	N/A

Summary

Ocugen beats enGene on 7 of the 13 factors compared between the two stocks.

How does enGene compare to Kyverna Therapeutics?

enGene (NASDAQ:ENGN) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, enGene had 4 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 5 mentions for enGene and 1 mentions for Kyverna Therapeutics. Kyverna Therapeutics' average media sentiment score of 1.34 beat enGene's score of 0.08 indicating that Kyverna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
enGene	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyverna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

enGene has a beta of -0.28, indicating that its share price is 128% less volatile than the broader market. Comparatively, Kyverna Therapeutics has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market.

enGene's return on equity of -56.06% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-56.06%	-45.64%
Kyverna Therapeutics	N/A	-81.88%	-64.87%

Kyverna Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.17	N/A
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A

64.2% of enGene shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 17.6% of Kyverna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

enGene currently has a consensus target price of $11.05, indicating a potential upside of 490.67%. Kyverna Therapeutics has a consensus target price of $30.00, indicating a potential upside of 314.36%. Given enGene's higher possible upside, equities analysts plainly believe enGene is more favorable than Kyverna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

enGene beats Kyverna Therapeutics on 8 of the 13 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENGN vs. The Competition

Export

Metric	enGene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$121.91M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.86	20.49	27.07	23.95
Price / Sales	N/A	300.33	515.72	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.72	7.92	10.62	6.14
Net Income	-$117.30M	$23.81M	$3.60B	$331.74M
7 Day Performance	-1.32%	-1.09%	-1.26%	-1.82%
1 Month Performance	8.72%	2.56%	1.07%	-1.45%
1 Year Performance	-51.43%	42.16%	23.63%	16.32%

enGene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENGN enGene	3.8297 of 5 stars	$1.87 +2.7%	$11.05 +490.7%	-50.7%	$121.91M	N/A	N/A	31
AQST Aquestive Therapeutics	2.9925 of 5 stars	$4.04 -0.5%	$8.50 +110.4%	-6.2%	$506.90M	$44.54M	N/A	160	Positive News
NVCT Nuvectis Pharma	3.456 of 5 stars	$18.29 -0.8%	$35.00 +91.4%	+131.2%	$485.23M	N/A	N/A	8	Gap Up
VALN Valneva	2.1197 of 5 stars	$5.11 -2.9%	$11.98 +134.3%	-24.7%	$484.89M	$197.56M	N/A	700
OCGN Ocugen	2.3322 of 5 stars	$1.43 +1.4%	$9.50 +564.3%	+30.4%	$484.08M	$4.41M	N/A	80	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENGN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGN) Competitors

ENGN vs. AQST, NVCT, VALN, OCGN, and KYTX

How does enGene compare to Aquestive Therapeutics?

Summary

How does enGene compare to Nuvectis Pharma?

Summary

How does enGene compare to Valneva?

Summary

How does enGene compare to Ocugen?

Summary

How does enGene compare to Kyverna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

enGene (ENGN) Competitors

ENGN vs. AQST, NVCT, VALN, OCGN, and KYTX

How does enGene compare to Aquestive Therapeutics?

Which has more volatility and risk, ENGN or AQST?

Does the media refer more to ENGN or AQST?

Which has preferable valuation and earnings, ENGN or AQST?

Do analysts rate ENGN or AQST?

Do insiders & institutionals have more ownership in ENGN or AQST?

Is ENGN or AQST more profitable?

Summary

How does enGene compare to Nuvectis Pharma?

Which has more risk and volatility, ENGN or NVCT?

Which has better earnings and valuation, ENGN or NVCT?

Is ENGN or NVCT more profitable?

Do insiders and institutionals hold more shares of ENGN or NVCT?

Does the media prefer ENGN or NVCT?

Do analysts prefer ENGN or NVCT?

Summary

How does enGene compare to Valneva?

Do analysts prefer ENGN or VALN?

Which has better valuation & earnings, ENGN or VALN?

Does the media prefer ENGN or VALN?

Do insiders and institutionals believe in ENGN or VALN?

Which has more volatility and risk, ENGN or VALN?

Is ENGN or VALN more profitable?

Summary

How does enGene compare to Ocugen?

Which has more risk & volatility, ENGN or OCGN?

Does the media refer more to ENGN or OCGN?

Is ENGN or OCGN more profitable?

Do institutionals and insiders hold more shares of ENGN or OCGN?

Do analysts rate ENGN or OCGN?

Which has better valuation and earnings, ENGN or OCGN?

Summary

How does enGene compare to Kyverna Therapeutics?

Does the media prefer ENGN or KYTX?

Which has more volatility and risk, ENGN or KYTX?

Is ENGN or KYTX more profitable?

Which has stronger earnings & valuation, ENGN or KYTX?

Do institutionals and insiders believe in ENGN or KYTX?

Do analysts recommend ENGN or KYTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENGN vs. The Competition

enGene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools